{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:57:51Z","timestamp":1781647071986,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["252300423887"],"award-info":[{"award-number":["252300423887"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303617"],"award-info":[{"award-number":["82303617"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multidrug resistance is the major cause of treatment failure in ovarian cancer. Overexpression of cyclin-dependent kinase (CDK) 9 has been observed in a variety of cancers and promotes tumor cell growth and proliferation by regulating transcription. However, the role of CDK9 in drug resistance of ovarian cancer remains unknown. In this study, the expression levels of CDK9 and related proteins were evaluated in two pairs of human ovarian cancer drug-resistant cell lines by western blot. We found that both drug resistant ovarian cancer cells expressed higher levels of CDK9 as compared with their parental drug sensitive cell lines. Additionally, inhibition of CDK9, with either siRNA or a CDK9 inhibitor LDC067, enhanced paclitaxel sensitivity in drug resistant ovarian cancer cells. This was also accompanied with a reduction in the phosphorylation of RNA polymerase II and Stat3, resulting in enhanced apoptosis. Furthermore, inhibition of CDK9 also decreased ovarian cancer spheroid formation and cell motility. These findings collectively indicate that inhibition of CDK9 can enhance paclitaxel sensitivity in drug resistant ovarian cancer cells by increasing apoptosis. CDK9 represents a promising target for overcome drug resistance in ovarian cancer.<\/jats:p>","DOI":"10.1038\/s41598-026-47843-6","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T02:06:41Z","timestamp":1775527601000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of CDK9 sensitizes multidrug resistant ovarian cancer cells to paclitaxel"],"prefix":"10.1038","volume":"16","author":[{"given":"Jinglu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis J.","family":"Hornicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huirong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"issue":"2025","key":"47843_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H. & Jemal, A. Cancer statistics, 2025. CA Cancer J. Clin. 75 (2025), 10\u201345 (2025).","journal-title":"CA Cancer J. Clin."},{"issue":"2009","key":"47843_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","volume":"27","author":"MA Bookman","year":"2009","unstructured":"Bookman, M. A. et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J. Clin. Oncol. 27 (2009), 1419\u20131425 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"2014","key":"47843_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1758834014544891","volume":"6","author":"S Sato","year":"2014","unstructured":"Sato, S. & Itamochi, H. Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy. Ther. Adv. Med. Oncol. 6 (2014), 293\u2013304 (2014).","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"2024","key":"47843_CR4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12943-024-01967-3","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol. Cancer. 23 (2024), 66 (2024).","journal-title":"Mol. Cancer"},{"issue":"2014","key":"47843_CR5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/gb4184","volume":"15","author":"M Malumbres","year":"2014","unstructured":"Malumbres, M. Cyclin-dependent kinases. Genome Biol. 15 (2014), 122 (2014).","journal-title":"Genome Biol."},{"issue":"2006","key":"47843_CR6","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2005.03.7689","volume":"24","author":"GI Shapiro","year":"2006","unstructured":"Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24 (2006), 1770\u20131783 (2006).","journal-title":"J. Clin. Oncol."},{"issue":"2005","key":"47843_CR7","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.cellsig.2005.02.005","volume":"17","author":"P Loyer","year":"2005","unstructured":"Loyer, P., Trembley, J. H., Katona, R., Kidd, V. J. & Lahti, J. M. Role of CDK\/cyclin complexes in transcription and RNA splicing. Cell. Signal. 17 (2005), 1033\u20131051 (2005).","journal-title":"Cell. Signal."},{"issue":"2009","key":"47843_CR8","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres, M. & Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer. 9 (2009), 153\u2013166 (2009).","journal-title":"Nat. Rev. Cancer"},{"issue":"2020","key":"47843_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.7150\/jca.35426","volume":"11","author":"S Shen","year":"2020","unstructured":"Shen, S. et al. Aberrant CDK9 expression within chordoma tissues and the therapeutic potential of a selective CDK9 inhibitor LDC000067. J. Cancer. 11 (2020), 132\u2013141 (2020).","journal-title":"J. Cancer"},{"issue":"2017","key":"47843_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.pharmthera.2017.02.008","volume":"173","author":"SR Whittaker","year":"2017","unstructured":"Whittaker, S. R., Mallinger, A., Workman, P. & Clarke, P. A. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol. Ther. 173 (2017), 83\u2013105 (2017).","journal-title":"Pharmacol. Ther."},{"issue":"2016","key":"47843_CR11","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","volume":"375","author":"RS Finn","year":"2016","unstructured":"Finn, R. S. et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl. J. Med. 375 (2016), 1925\u20131936 (2016).","journal-title":"N Engl. J. Med."},{"issue":"2015","key":"47843_CR12","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/leu.2015.31","volume":"29","author":"J Flynn","year":"2015","unstructured":"Flynn, J. et al. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. Leukemia 29 (2015), 1524\u20131529 (2015).","journal-title":"Leukemia"},{"issue":"2005","key":"47843_CR13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.tibs.2005.09.005","volume":"30","author":"M Malumbres","year":"2005","unstructured":"Malumbres, M. & Barbacid, M. Mammalian cyclin-dependent kinases. Trends Biochem. Sci. 30 (2005), 630\u2013641 (2005).","journal-title":"Trends Biochem. Sci."},{"issue":"2009","key":"47843_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1747-1028-4-19","volume":"4","author":"J Kohoutek","year":"2009","unstructured":"Kohoutek, J. P-TEFb- the final frontier. Cell. Div. 4 (2009), 19 (2009).","journal-title":"Cell. Div."},{"issue":"2019","key":"47843_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ebiom.2018.12.022","volume":"39","author":"H Ma","year":"2019","unstructured":"Ma, H., Seebacher, N. A., Hornicek, F. J. & Duan, Z. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma. EBioMedicine 39 (2019), 182\u2013193 (2019).","journal-title":"EBioMedicine"},{"issue":"2024","key":"47843_CR16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41416-024-02810-8","volume":"131","author":"R Rahman","year":"2024","unstructured":"Rahman, R. et al. CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer. Br. J. Cancer. 131 (2024), 1092\u20131105 (2024).","journal-title":"Br. J. Cancer"},{"issue":"2024","key":"47843_CR17","doi-asserted-by":"publisher","first-page":"116342","DOI":"10.1016\/j.bcp.2024.116342","volume":"226","author":"RL Walker","year":"2024","unstructured":"Walker, R. L., Hornicek, F. J. & Duan, Z. Transcriptional regulation and therapeutic potential of cyclin-dependent kinase 9 (CDK9) in sarcoma. Biochem. Pharmacol. 226 (2024), 116342 (2024).","journal-title":"Biochem. Pharmacol."},{"issue":"2023","key":"47843_CR18","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1039\/D3TB00046J","volume":"11","author":"Z Zhang","year":"2023","unstructured":"Zhang, Z. et al. Biomimetic black phosphorus nanosheets codeliver CDK9 and BRD4 inhibitors for gastric cancer targeted therapy. J. Mater. Chem. B. 11 (2023), 6131\u20136140 (2023).","journal-title":"J. Mater. Chem. B"},{"issue":"2017","key":"47843_CR19","doi-asserted-by":"publisher","first-page":"101042831769430","DOI":"10.1177\/1010428317694304","volume":"39","author":"AL Kretz","year":"2017","unstructured":"Kretz, A. L. et al. CDK9 is a prognostic marker and therapeutic target in pancreatic cancer. Tumour biology: J. Int. Soc. Oncodevelopmental Biology Med. 39 (2017), 1010428317694304 (2017).","journal-title":"Tumour biology: J. Int. Soc. Oncodevelopmental Biology Med."},{"issue":"2022","key":"47843_CR20","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1038\/s41401-021-00796-0","volume":"43","author":"YL Shen","year":"2022","unstructured":"Shen, Y. L. et al. Targeting cyclin-dependent kinase 9 in cancer therapy. Acta Pharmacol. Sin. 43 (2022), 1633\u20131645 (2022).","journal-title":"Acta Pharmacol. Sin"},{"issue":"2024","key":"47843_CR21","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/0008-5472.CAN-23-0650","volume":"84","author":"A Soosainathan","year":"2024","unstructured":"Soosainathan, A. et al. Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers. Cancer Res. 84 (2024), 17\u201325 (2024).","journal-title":"Cancer Res."},{"issue":"2024","key":"47843_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40364-024-00589-7","volume":"12","author":"V Jiang","year":"2024","unstructured":"Jiang, V. et al. The CDK9 inhibitor enitociclib overcomes resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma. Biomark. Res. 12 (2024), 62 (2024).","journal-title":"Biomark. Res."},{"issue":"2023","key":"47843_CR23","doi-asserted-by":"publisher","first-page":"2219470","DOI":"10.1080\/15384047.2023.2219470","volume":"24","author":"L Xiao","year":"2023","unstructured":"Xiao, L., Liu, Y., Chen, H. & Shen, L. Targeting CDK9 with selective inhibitors or degraders in tumor therapy: an overview of recent developments. Cancer Biol. Ther. 24 (2023), 2219470 (2023).","journal-title":"Cancer Biol. Ther."},{"issue":"2019","key":"47843_CR24","doi-asserted-by":"publisher","first-page":"5990","DOI":"10.1096\/fj.201801789RR","volume":"33","author":"J Wang","year":"2019","unstructured":"Wang, J., Dean, D. C., Hornicek, F. J., Shi, H. & Duan, Z. Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer. FASEB J. 33 (2019), 5990\u20136000 (2019).","journal-title":"FASEB J."},{"issue":"2017","key":"47843_CR25","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.bbrc.2016.11.049","volume":"482","author":"S Cao","year":"2017","unstructured":"Cao, S. et al. Inhibition of CDK9 induces apoptosis and potentiates the effect of cisplatin in hypopharyngeal carcinoma cells. Biochem. Biophys. Res. Commun. 482 (2017), 536\u2013541 (2017).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2011","key":"47843_CR26","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/leu.2010.290","volume":"25","author":"E Walsby","year":"2011","unstructured":"Walsby, E., Lazenby, M., Pepper, C. & Burnett, A. K. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine. Leukemia 25 (2011), 411\u2013419 (2011).","journal-title":"Leukemia"},{"issue":"2005","key":"47843_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/jcp.20224","volume":"203","author":"H Liu","year":"2005","unstructured":"Liu, H. & Herrmann, C. H. Differential localization and expression of the Cdk9 42k and 55k isoforms. J. Cell. Physiol. 203 (2005), 251\u2013260 (2005).","journal-title":"J. Cell. Physiol."},{"issue":"2011","key":"47843_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/978-1-61779-080-5_34","volume":"731","author":"IV Bijnsdorp","year":"2011","unstructured":"Bijnsdorp, I. V., Giovannetti, E. & Peters, G. J. Analysis of drug interactions. Methods Mol. Biol. (Clifton, N. J.) 731 (2011), 421\u2013434 (2011).","journal-title":"Methods Mol. Biol."},{"issue":"2014","key":"47843_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/cbdd.12330","volume":"84","author":"R Jorda","year":"2014","unstructured":"Jorda, R. et al. Arylazopyrazole AAP1742 inhibits CDKs and induces apoptosis in multiple myeloma cells via Mcl-1 downregulation. Chem. Biol. Drug Des. 84 (2014), 402\u2013408 (2014).","journal-title":"Chem. Biol. Drug Des."},{"issue":"202","key":"47843_CR30","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13048-021-00827-8","volume":"14","author":"SK Parvathareddy","year":"2021","unstructured":"Parvathareddy, S. K. et al. Cyclin-dependent kinase 9 (CDK9) predicts recurrence in Middle Eastern epithelial ovarian cancer. J. Ovarian Res. 14 (202), 69 (2021).","journal-title":"J. Ovarian Res."},{"issue":"2019","key":"47843_CR31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/jor.24189","volume":"37","author":"X Li","year":"2019","unstructured":"Li, X., Seebacher, N. A., Xiao, T., Hornicek, F. J. & Duan, Z. Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma. J. Orthop. Res. 37 (2019), 510\u2013521 (2019).","journal-title":"J. Orthop. Res."},{"issue":"2024","key":"47843_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41419-024-06724-4","volume":"15","author":"L Valdez Capuccino","year":"2024","unstructured":"Valdez Capuccino, L. et al. CDK9 inhibition as an effective therapy for small cell lung cancer. Cell. Death Dis. 15 (2024), 345 (2024).","journal-title":"Cell. Death Dis."},{"issue":"202","key":"47843_CR33","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.3390\/cancers13153906","volume":"13","author":"J Padmanabhan","year":"2021","unstructured":"Padmanabhan, J. et al. Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells. Cancers (Basel). 13 (202), 3906 (2021).","journal-title":"Cancers (Basel)"},{"issue":"2012","key":"47843_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ygyno.2012.05.030","volume":"127","author":"KC Bible","year":"2012","unstructured":"Bible, K. C. et al. Mayo Phase 2 Consortium (P2C), North Central Cancer Treatment Group (NCCTG), A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261. Gynecol. Oncol. 127 (2012), 55\u201362 (2012).","journal-title":"Gynecol. Oncol."},{"issue":"2019","key":"47843_CR35","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.bbrc.2019.09.118","volume":"520","author":"H Song","year":"2019","unstructured":"Song, H. et al. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy. Biochem. Biophys. Res. Commun. 520 (2019), 250\u2013256 (2019).","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2022","key":"47843_CR36","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1158\/1078-0432.CCR-21-3617","volume":"28","author":"JR Diamond","year":"2022","unstructured":"Diamond, J. R. et al. First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy. Clin. Cancer Res. 28 (2022), 1285\u20131293 (2022).","journal-title":"Clin. Cancer Res."},{"issue":"2025","key":"47843_CR37","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1182\/bloodadvances.2024014633","volume":"9","author":"MS Davids","year":"2025","unstructured":"Davids, M. S. et al. A phase 1 study of the CDK9 inhibitor voruciclib in relapsed\/refractory acute myeloid leukemia and B-cell malignancies. Blood Adv. 9 (2025), 820\u2013832 (2025).","journal-title":"Blood Adv."},{"issue":"2025","key":"47843_CR38","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-025-01724-z","volume":"18","author":"BJ Ball","year":"2025","unstructured":"Ball, B. J. et al. Phase I first-in-human dose escalation study of the oral casein kinase 1\u03b1 and cyclin dependent kinase 7\/9 inhibitor BTX A51 in advanced MDS and AML. J. Hematol. Oncol. 18 (2025), 73 (2025).","journal-title":"J. Hematol. Oncol."},{"issue":"2025","key":"47843_CR39","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1158\/2767-9764.CRC-25-0015","volume":"5","author":"GJ Hanna","year":"2025","unstructured":"Hanna, G. J. et al. Safety and Efficacy of a Selective Inhibitor of Cyclin-dependent Kinase 9 (KB-0742) in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma. Cancer Res. Commun. 5 (2025), 767\u2013773 (2025).","journal-title":"Cancer Res. Commun."},{"issue":"2014","key":"47843_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/bph.12408","volume":"171","author":"TK Albert","year":"2014","unstructured":"Albert, T. K. et al. Characterization of molecular and cellular functions of the cyclin-dependent kinase CDK9 using a novel specific inhibitor. Br. J. Pharmacol. 171 (2014), 55\u201368 (2014).","journal-title":"Br. J. Pharmacol."},{"issue":"2015","key":"47843_CR41","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.bcp.2015.04.019","volume":"96","author":"AH Wagner","year":"2015","unstructured":"Wagner, A. H. et al. JAK1\/STAT3 activation directly inhibits IL-12 production in dendritic cells by preventing CDK9\/P-TEFb recruitment to the p35 promoter. Biochem. Pharmacol. 96 (2015), 52\u201364 (2015).","journal-title":"Biochem. Pharmacol."},{"issue":"2004","key":"47843_CR42","doi-asserted-by":"publisher","first-page":"7391","DOI":"10.1038\/sj.onc.1207972","volume":"23","author":"S Giraud","year":"2004","unstructured":"Giraud, S., Hurlstone, A., Avril, S. & Coqueret, O. Implication of BRG1 and cdk9 in the STAT3-mediated activation of the p21waf1 gene. Oncogene 23 (2004), 7391\u20137398 (2004).","journal-title":"Oncogene"},{"issue":"2006","key":"47843_CR43","doi-asserted-by":"publisher","first-page":"5055","DOI":"10.1158\/1078-0432.CCR-06-0861","volume":"12","author":"Z Duan","year":"2006","unstructured":"Duan, Z. et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin. Cancer Res. 12 (2006), 5055\u20135063 (2006).","journal-title":"Clin. Cancer Res."},{"issue":"2008","key":"47843_CR44","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1111\/j.1742-4658.2008.06349.x","volume":"275","author":"SN Kolomeichuk","year":"2008","unstructured":"Kolomeichuk, S. N., Terrano, D. T., Lyle, C. S., Sabapathy, K. & Chambers, T. C. Distinct signaling pathways of microtubule inhibitors\u2013vinblastine and Taxol induce JNK-dependent cell death but through AP-1-dependent and AP-1-independent mechanisms, respectively. FEBS J. 275 (2008), 1889\u20131899 (2008).","journal-title":"FEBS J."},{"issue":"2003","key":"47843_CR45","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nrc1075","volume":"3","author":"P Friedl","year":"2003","unstructured":"Friedl, P. & Wolf, K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer. 3 (2003), 362\u2013374 (2003).","journal-title":"Nat. Rev. Cancer"},{"issue":"2018","key":"47843_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ygyno.2018.04.557","volume":"150","author":"J Wang","year":"2018","unstructured":"Wang, J. et al. Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer. Gynecol. Oncol. 150 (2018), 143\u2013150 (2018).","journal-title":"Gynecol. Oncol."},{"issue":"2004","key":"47843_CR47","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1158\/1535-7163.833.3.7","volume":"3","author":"Z Duan","year":"2004","unstructured":"Duan, Z., Brakora, K. A. & Seiden, M. V. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol. Cancer Ther. 3 (2004), 833\u2013838 (2004).","journal-title":"Mol. Cancer Ther."},{"issue":"2017","key":"47843_CR48","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s13402-017-0316-x","volume":"40","author":"Y Gao","year":"2017","unstructured":"Gao, Y. et al. Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss. Cell. Oncol. (Dordr). 40 (2017), 209\u2013218 (2017).","journal-title":"Cell. Oncol. (Dordr)"},{"key":"47843_CR49","first-page":"2640","volume":"8","author":"AE Stephen","year":"2002","unstructured":"Stephen, A. E. et al. Highly purified m\u00fcllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin. Cancer Res. 8, 2640\u20132646 (2002).","journal-title":"Clin. Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47843-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47843-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47843-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:33:38Z","timestamp":1781645618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47843-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47843"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47843-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"11 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}}],"article-number":"11671"}}